Elutia Inc.

United States of America

Back to Profile

1-34 of 34 for Elutia Inc. Sort by
Query
Aggregations
IP Type
        Patent 30
        Trademark 4
Jurisdiction
        United States 32
        World 2
Date
2024 3
2023 1
2021 1
Before 2020 29
IPC Class
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells 22
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof 21
A61L 27/54 - Biologically active materials, e.g. therapeutic substances 21
A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva 20
A61L 27/38 - Animal cells 18
See more

1.

ELUPRO

      
Application Number 1825231
Status Registered
Filing Date 2024-11-06
Registration Date 2024-11-06
Owner Elutia Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Medical products, namely, living tissue based biomaterial encasement structures intended to envelop electrical devices and implant the enveloped electrical devices in mammals.

2.

ELUPRO

      
Serial Number 98549074
Status Registered
Filing Date 2024-05-14
Registration Date 2025-10-28
Owner Elutia Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Medical products, namely, living tissue based biomaterial encasement structures intended to envelop electrical devices and implant the enveloped electrical devices in mammals

3.

ELUTIA

      
Application Number 1784683
Status Registered
Filing Date 2024-01-30
Registration Date 2024-01-30
Owner Elutia Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Drug-eluting biologics; drug-eluting biologics, namely bone, skin, tissue, tendons and other materials derived from living organisms that are impregnated with a drug with pharmacotherapeutic effect; drug-eluting biologics, namely materials derived from living organisms that are impregnated with antibiotics; drug-eluting biologics, namely materials derived from living organisms that are impregnated with hemostatics; drug-eluting biologics, namely materials derived from living organisms that are impregnated with chemotherapeutics.

4.

ELUTIA

      
Serial Number 98321498
Status Registered
Filing Date 2023-12-19
Registration Date 2025-11-11
Owner Elutia Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Drug-eluting biologics, namely bone, skin, tendons and other tissues derived from living organisms that are impregnated with a drug with pharmacotherapeutic effect; Drug-eluting biologics, namely bone, skin, tendons and other tissues derived from living organisms that are impregnated with antibiotics; Drug-eluting biologics, namely bone, skin, tendons and other tissues derived from living organisms that are impregnated with hemostatics; Drug-eluting biologics, namely bone, skin, tendons and other tissues derived from living organisms that are impregnated with chemotherapeutics.

5.

Placental tissue compositions and methods

      
Application Number 17183927
Grant Number 12247225
Status In Force
Filing Date 2021-02-24
First Publication Date 2021-09-02
Grant Date 2025-03-11
Owner ELUTIA INC. (USA)
Inventor
  • Zhang, Ji
  • Deegan, Daniel
  • Roberts, Darryl

Abstract

Disclosed herein are methods and compositions of decellularized preterm placental tissue. Compositions comprise decellularized regenerative tissue derived from animal placentas that are harvested preterm, i.e., before the completion of the normal duration of gestation. Preterm placental tissue may contain a high level of growth factors and other beneficial components that aid in tissue regeneration and healing.

IPC Classes  ?

  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12M 3/04 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers

6.

Extracellular matrix sheet structures

      
Application Number 16225918
Grant Number 11045580
Status In Force
Filing Date 2018-12-19
First Publication Date 2019-04-25
Grant Date 2021-06-29
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G.

Abstract

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/37 - Digestive system
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • C07H 15/00 - Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61L 27/34 - Macromolecular materials
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61L 31/04 - Macromolecular materials
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
  • A61K 38/18 - Growth factorsGrowth regulators

7.

Extracellular matrix sheet structures

      
Application Number 15496297
Grant Number 10159764
Status In Force
Filing Date 2017-04-25
First Publication Date 2017-10-26
Grant Date 2018-12-25
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A sheet structure formed from an extracellular matrix (ECM) composition that includes acellular ECM derived from small intestine submucosa (SIS) tissue, gentamicin and vancomycin. The sheet structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of new tissue and tissue structures with site-specific structural and functional properties, when the tissue structure is delivered to the damaged biological tissue.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/37 - Digestive system
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • C07H 15/00 - Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61L 31/04 - Macromolecular materials
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
  • A61K 38/18 - Growth factorsGrowth regulators

8.

Cardiovascular prostheses

      
Application Number 15386640
Grant Number 10143778
Status In Force
Filing Date 2016-12-21
First Publication Date 2017-04-13
Grant Date 2018-12-04
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

IPC Classes  ?

  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61F 2/06 - Blood vessels
  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61L 27/34 - Macromolecular materials
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/58 - Materials at least partially resorbable by the body
  • A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
  • A61L 27/38 - Animal cells
  • A61L 27/50 - Materials characterised by their function or physical properties

9.

Cardiovascular prostheses

      
Application Number 15386750
Grant Number 10201636
Status In Force
Filing Date 2016-12-21
First Publication Date 2017-04-13
Grant Date 2019-02-12
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

IPC Classes  ?

  • A61F 2/24 - Heart valves
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 9/00 - Medicinal preparations characterised by special physical form

10.

Cardiovascular prostheses

      
Application Number 15386902
Grant Number 09867906
Status In Force
Filing Date 2016-12-21
First Publication Date 2017-04-13
Grant Date 2018-01-16
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

IPC Classes  ?

  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/58 - Materials at least partially resorbable by the body
  • A61F 2/24 - Heart valves
  • A61F 2/06 - Blood vessels
  • A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
  • A61F 2/02 - Prostheses implantable into the body
  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

11.

Cardiovascular prostheses

      
Application Number 15386960
Grant Number 09919079
Status In Force
Filing Date 2016-12-21
First Publication Date 2017-04-13
Grant Date 2018-03-20
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

IPC Classes  ?

  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
  • A61F 2/24 - Heart valves
  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
  • A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61F 2/02 - Prostheses implantable into the body

12.

Extracellular matrix encasement structures and methods

      
Application Number 14833373
Grant Number 09662419
Status In Force
Filing Date 2015-08-24
First Publication Date 2015-12-17
Grant Date 2017-05-30
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells

13.

Extracellular matrix encasement structures and methods

      
Application Number 14833404
Grant Number 09669133
Status In Force
Filing Date 2015-08-24
First Publication Date 2015-12-17
Grant Date 2017-06-06
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A pouch structure formed from extracellular matrix (ECM) derived from small intestine submucosa (SIS) that includes an internal region configured to receive a medical device therein. The pouch structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of tissue structures with site-specific structural and functional properties, when implanted in a subject.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/37 - Digestive system
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells

14.

Extracellular matrix (ECM) structures for tissue regeneration

      
Application Number 14452794
Grant Number 09700654
Status In Force
Filing Date 2014-08-06
First Publication Date 2015-12-17
Grant Date 2017-07-11
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor
  • Matheny, Robert G
  • Ferrante, Craig N

Abstract

A multi-sheet extracellular matrix (ECM) structure for tissue regeneration, the ECM structure having joined first and second ECM sheet members and an agent dispersal network disposed between the sheets, the dispersal network being configured to receive and transfer a bioactive agent through the network and, when the ECM structure is attached to tissue, administer the bioactive agent to the tissue.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/37 - Digestive system
  • C07K 1/00 - General processes for the preparation of peptides
  • A61L 27/56 - Porous or cellular materials
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61L 27/38 - Animal cells
  • A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
  • A61K 9/70 - Web, sheet or filament bases
  • A61F 2/02 - Prostheses implantable into the body
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

15.

Extracellular matrix encasement structures and methods

      
Application Number 14833340
Grant Number 09636437
Status In Force
Filing Date 2015-08-24
First Publication Date 2015-12-17
Grant Date 2017-05-02
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

IPC Classes  ?

  • A61F 13/00 - Bandages or dressingsAbsorbent pads
  • A61K 35/37 - Digestive system
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides

16.

Extracellular matrix encasement structures and methods

      
Application Number 14833354
Grant Number 09682171
Status In Force
Filing Date 2015-08-24
First Publication Date 2015-12-17
Grant Date 2017-06-20
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

IPC Classes  ?

  • A61F 13/00 - Bandages or dressingsAbsorbent pads
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells

17.

Extracellular matrix (ECM) structures for tissue regeneration

      
Application Number 14685714
Grant Number 10293084
Status In Force
Filing Date 2015-04-14
First Publication Date 2015-08-06
Grant Date 2019-05-21
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G.

Abstract

An extracellular matrix (ECM) structure for tissue regeneration, the ECM structure having a a sheet member comprising small intestine submucosa (SIS), the SIS sheet member being folded and laminated proximate the sheet member edge, wherein a folded laminated ECM structure having a cavity therein is formed, the ECM structure further including an ECM composition that is disposed in the ECM structure cavity, the ECM composition including liver basement membrane, urinary bladder submucosa, a mesenchymal stem cell and a growth factor.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/37 - Digestive system
  • C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
  • C07H 15/00 - Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 31/00 - Materials for other surgical articles
  • A61F 2/02 - Prostheses implantable into the body
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

18.

Extracellular matrix encasement structures and methods

      
Application Number 14685755
Grant Number 09662418
Status In Force
Filing Date 2015-04-14
First Publication Date 2015-08-06
Grant Date 2017-05-30
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/37 - Digestive system
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells

19.

Compositions and methods for preventing cardiac arrhythmia

      
Application Number 14671360
Grant Number 09308225
Status In Force
Filing Date 2015-03-27
First Publication Date 2015-07-16
Grant Date 2016-04-12
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 38/20 - Interleukins
  • A61K 38/21 - Interferons
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 35/407 - LiverHepatocytes
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
  • A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
  • A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
  • A61K 31/47 - QuinolinesIsoquinolines
  • A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells

20.

Compositions and methods for preventing cardiac arrhythmia

      
Application Number 14621925
Grant Number 09119841
Status In Force
Filing Date 2015-02-13
First Publication Date 2015-06-18
Grant Date 2015-09-01
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61K 35/407 - LiverHepatocytes
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • A61K 31/47 - QuinolinesIsoquinolines
  • A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 38/20 - Interleukins
  • A61K 38/21 - Interferons
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
  • A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
  • A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam

21.

Compositions and methods for preventing cardiac arrhythmia

      
Application Number 14621893
Grant Number 09084841
Status In Force
Filing Date 2015-02-13
First Publication Date 2015-06-11
Grant Date 2015-07-21
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/37 - Digestive system
  • A61K 35/407 - LiverHepatocytes
  • A61P 9/06 - Antiarrhythmics
  • A61P 3/06 - Antihyperlipidemics
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

22.

Compositions and methods for preventing cardiac arrhythmia

      
Application Number 14622167
Grant Number 09089549
Status In Force
Filing Date 2015-02-13
First Publication Date 2015-06-04
Grant Date 2015-07-28
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/37 - Digestive system
  • A61K 35/407 - LiverHepatocytes
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 9/00 - Medicinal preparations characterised by special physical form

23.

Compositions and methods for preventing cardiac arrhythmia

      
Application Number 14622118
Grant Number 09078873
Status In Force
Filing Date 2015-02-13
First Publication Date 2015-06-04
Grant Date 2015-07-14
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/37 - Digestive system
  • A61K 35/407 - LiverHepatocytes
  • A61P 9/06 - Antiarrhythmics
  • A61P 3/06 - Antihyperlipidemics
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 9/00 - Medicinal preparations characterised by special physical form

24.

Extracellular matrix encasement structures and methods

      
Application Number 14571639
Grant Number 09744264
Status In Force
Filing Date 2014-12-16
First Publication Date 2015-04-09
Grant Date 2017-08-29
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/38 - Animal cells
  • A61L 27/34 - Macromolecular materials
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 31/16 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61N 1/375 - Constructional arrangements, e.g. casings
  • A61L 27/22 - Polypeptides or derivatives thereof
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/37 - Digestive system
  • A61K 38/18 - Growth factorsGrowth regulators

25.

Sterilized and decellularized extracellular matrix for treating cardiac arrhythmia

      
Application Number 13925993
Grant Number 09446078
Status In Force
Filing Date 2013-06-25
First Publication Date 2014-12-25
Grant Date 2016-09-20
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/407 - LiverHepatocytes
  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 38/20 - Interleukins
  • A61K 38/21 - Interferons
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
  • A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
  • A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
  • A61K 31/47 - QuinolinesIsoquinolines
  • A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells

26.

Extracellular matrix encasement structures and methods

      
Application Number 13896424
Grant Number 09283302
Status In Force
Filing Date 2013-05-17
First Publication Date 2014-11-20
Grant Date 2016-03-15
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A remodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region and at least one lead conduit, the internal region being configured to receive a device therein, the lead conduit being configures to receive at least one device lead therein, the bioremodelable material comprising an extracellular matrix (ECM) composition that includes an ECM component derived from a mammalian source.

IPC Classes  ?

  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61F 13/00 - Bandages or dressingsAbsorbent pads
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • A61N 1/362 - Heart stimulators
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 31/00 - Materials for other surgical articles
  • A61F 2/02 - Prostheses implantable into the body
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides

27.

Extracellular matrix (ECM) structures for tissue regeneration

      
Application Number 14306368
Grant Number 09333277
Status In Force
Filing Date 2014-06-17
First Publication Date 2014-11-13
Grant Date 2016-05-10
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

An extracellular matrix (ECM) structure for tissue regeneration, the ECM structure having a a sheet member comprising small intestine submucosa (SIS), the SIS sheet member being folded and laminated proximate the sheet member edge, wherein a folded laminated ECM structure having a cavity therein is formed, the ECM structure further including an ECM composition that is disposed in the ECM structure cavity, the ECM composition including liver basement membrane, urinary bladder submucosa, a mesenchymal stem cell and a growth factor.

IPC Classes  ?

  • A61F 13/00 - Bandages or dressingsAbsorbent pads
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 31/00 - Materials for other surgical articles
  • A61F 2/02 - Prostheses implantable into the body
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva

28.

Extracellular matrix encasement structures and methods

      
Application Number 13573566
Grant Number 09066993
Status In Force
Filing Date 2012-09-24
First Publication Date 2013-01-24
Grant Date 2015-06-30
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G

Abstract

A remodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch having an internal region configured to receive a device therein, the bioremodelable material comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least a bioactive component selected from the group consisting of a statin and a chitin derivative.

IPC Classes  ?

  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61F 13/00 - Bandages or dressingsAbsorbent pads
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
  • A61N 1/362 - Heart stimulators
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 31/00 - Materials for other surgical articles
  • A61F 2/02 - Prostheses implantable into the body
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61F 2/24 - Heart valves
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva

29.

Acellular dermal allografts and method of preparation

      
Application Number 13389937
Grant Number 09888999
Status In Force
Filing Date 2010-01-04
First Publication Date 2013-01-10
Grant Date 2018-02-13
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor
  • Forsell, James
  • Fan, Frank

Abstract

A method for preparing a sterilized human acellular dermal allograft where the dermal allograft is sterilized by irradiation and has a greatly reduced bio-burden and enzymatic and antigenic activity. This product line of allografts can be easily used by surgeons in soft tissue replacement or repair and has an extended shelf life, of up to at least about three years.

IPC Classes  ?

30.

Processed ECM materials with enhanced component profiles

      
Application Number 13488519
Grant Number 08455008
Status In Force
Filing Date 2012-06-05
First Publication Date 2012-12-06
Grant Date 2013-06-04
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Johnson, Chad E.

Abstract

Described are medical graft materials and devices having improved properties relating to their component profiles.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 35/37 - Digestive system

31.

Drug eluting patch for the treatment of localized tissue disease or defect

      
Application Number 13328287
Grant Number 09532943
Status In Force
Filing Date 2011-12-16
First Publication Date 2012-06-21
Grant Date 2017-01-03
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert

Abstract

A polymeric matrix for delivery of an HMG CoA reductase inhibitor such as a statin to tissue such as cardiac tissue in need thereof for the treatment or prevention of a disease or defect such as atrial fibrillation has been developed. In the preferred embodiment, a statin is delivered by means of a patch sutured to cardiac tissue at the time of cardiothoracic surgery. In the most preferred embodiment, the patch is a biodegradable material providing controlled or sustained release over a prolonged period of time, such as a week. Suitable materials include extracellular matrix, or other biodegradable hydrogels or polymeric materials providing sustained or controlled release of statin at the site of application.

IPC Classes  ?

  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 9/00 - Medicinal preparations characterised by special physical form

32.

Laminate sheet articles for tissue regeneration

      
Application Number 13033102
Grant Number 08758448
Status In Force
Filing Date 2011-02-23
First Publication Date 2012-01-19
Grant Date 2014-06-24
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Matheny, Robert G.

Abstract

The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue.

IPC Classes  ?

  • A61F 2/02 - Prostheses implantable into the body
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells

33.

Compositions and methods for preventing cardiac arrhythmia

      
Application Number 12707427
Grant Number 08980296
Status In Force
Filing Date 2010-02-17
First Publication Date 2010-09-16
Grant Date 2015-03-17
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor
  • Matheny, Robert G.
  • Lewis, Beecher C.

Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

IPC Classes  ?

  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 38/20 - Interleukins
  • A61K 38/21 - Interferons
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

34.

Processed ECM materials with enhanced component profiles

      
Application Number 12178321
Grant Number 08192763
Status In Force
Filing Date 2008-07-23
First Publication Date 2008-11-20
Grant Date 2012-06-05
Owner
  • ELUTIA INC. (USA)
  • ELUTIA MED LLC (USA)
Inventor Johnson, Chad E.

Abstract

Described are medical graft materials and devices having improved properties relating to their component profiles.

IPC Classes  ?

  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
  • A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]